Justin Roth
Overview
Explore the profile of Justin Roth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fielding L, Menard M, Roth J, Iuliano M, Dehay B, Aguilar-Calvo P, et al.
Neurobiol Dis
. 2025 Jan;
206:106820.
PMID: 39889858
α-Synuclein (α-syn) can form amyloid fibrils. Lewy bodies and Lewy neurites containing aggregated α-syn are pathological markers of Parkinson's Disease and Dementia with Lewy Bodies. To better understand the role...
2.
Luhmann S, Roth J, DeFreitas D, McCormick S
Spine Deform
. 2021 Sep;
10(2):369-375.
PMID: 34480333
Purpose: To assess if the preservation of preoperative kyphosis within the cephalad two motion segments of instrumented posterior spinal fusions (PSF), for idiopathic scoliosis (IS), would be associated with lower...
3.
Roth J, Goldman B, Zirkle Jr L, Schlechter J, Ibrahim J, Shearer D
SICOT J
. 2018 Dec;
4:55.
PMID: 30500327
Background: As the population ages, the developing world industrializes, and more urban centers emerge, the burden of orthopedic trauma will steadily increase. SIGN Fracture Care International has developed a unique...
4.
Ghonime M, Jackson J, Shah A, Roth J, Li M, Saunders U, et al.
Transl Oncol
. 2017 Dec;
11(1):86-93.
PMID: 29216507
Malignant gliomas are the most common primary brain tumor and are characterized by rapid and highly invasive growth. Because of their poor prognosis, new therapeutic strategies are needed. Oncolytic virotherapy...
5.
Cassady K, Bauer D, Roth J, Chambers M, Shoeb T, Coleman J, et al.
Mol Ther Oncolytics
. 2017 Mar;
5:1-10.
PMID: 28345027
Oncolytic herpes simplex virus (oHSV) type I constructs are investigational anti-neoplastic agents for a variety of malignancies, including malignant glioma. Clinical trials to date have supported the safety of these...
6.
Sawant A, Schafer C, Jin T, Zmijewski J, Tse H, Roth J, et al.
Cancer Res
. 2013 Oct;
73(22):6609-20.
PMID: 24085788
Chemoresistance due to heterogeneity of the tumor microenvironment (TME) hampers the long-term efficacy of first-line therapies for lung cancer. Current combination therapies for lung cancer provide only modest improvement in...
7.
Komarova S, Roth J, Alvarez R, Curiel D, Pereboeva L
J Ovarian Res
. 2010 May;
3:12.
PMID: 20500878
Background: Mesenchymal Progenitor/Stem Cells (MSC) respond to homing cues providing an important mechanism to deliver therapeutics to sites of injury and tumors. This property has been confirmed by many investigators,...
8.
Gao Y, Lobritz M, Roth J, Abreha M, Nelson K, Nankya I, et al.
J Virol
. 2008 Jan;
82(6):2938-51.
PMID: 18199654
Small interfering RNAs (siRNAs) have been shown to effectively inhibit human immunodeficiency virus type 1 (HIV-1) replication in vitro. The mechanism(s) for this inhibition is poorly understood, as siRNAs may...
9.
An F, Folarin H, Compitello N, Roth J, Gerson S, McCrae K, et al.
J Virol
. 2006 Apr;
80(10):4833-46.
PMID: 16641275
Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease. Most KS tumor cells are latently infected with KSHV and are of...